BEDMINSTER, NJ – JULY 30: Mallinckrodt Pharmaceuticals office is seen on Tuesday, July 30, 2019, in Bedminster, New Jersey.
The Washington Post | The Washington Post | Getty Images
Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued at nearly $7 billion to boost scale for selling their branded drugs.
Endo shareholders will get $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion, the companies said on Thursday.
The new company, expected to generate $3.6 billion in 2025 revenue, will combine their branded drugs businesses, such as Endo’s testosterone injection Aveed and Mallinckrodt’s Acthar gel and kidney disease therapy Terlivaz.
The deal will “create a larger and more diversified entity with the scale and resources needed to unlock the full potential of both companies,” Mallinckrodt CEO Siggi Olafsson said.
Both companies also sell generic treatments, including highly regulated drugs such as opioids.
They plan to combine their generic drug businesses and Endo’s sterile injectables unit into another company that will be separated after the closing of the deal.
Dublin-based Mallinckrodt went bankrupt twice – once in 2020 due to its high debt load and litigation over allegedly deceptive marketing of highly addictive generic opioids and again in 2023 due to declining sales of its key branded drugs, including Acthar Gel.
As part of its second restructuring, Mallinckrodt was able to trim $1 billion from its previously agreed upon opioid settlement that resolved about 3,000 lawsuits.
Endo filed for bankruptcy in 2022 and completed its financial restructuring last year.
The combined company will benefit from Mallinckrodt and Endo’s “deep expertise in complex, highly regulated products, as well as a strong compliance culture”, they said in a statement on Thursday.
Endo will become a wholly owned unit of Mallinckrodt, with Olafsson serving as CEO of the combined company after the deal’s expected close in the second half of 2025.
The new company will be listed on the New York Stock Exchange.
Lazard served as Mallinckrodt’s financial adviser, while Goldman Sachs & Co. LLC served as Endo’s financial adviser.
Discover more from Latest News Today
Subscribe to get the latest posts sent to your email.
